Compare · AGL vs MGRX
AGL vs MGRX
Side-by-side comparison of agilon health inc. (AGL) and Mangoceuticals Inc. (MGRX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AGL and MGRX operate in Misc Health and Biotechnology Services (Health Care), so they compete in similar markets.
- AGL is the larger of the two at $435.2M, about 61.5x MGRX ($7.1M).
- Over the past year, AGL is down 72.9% and MGRX is down 75.8% - AGL leads by 2.9 points.
- AGL has hit the wire 7 times in the past 4 weeks while MGRX has been quiet.
- AGL has more recent analyst coverage (25 ratings vs 0 for MGRX).
PerformanceAGL-72.94%MGRX-75.84%
2025-04-28+0.00%2026-04-24
- Company
- agilon health inc.
- Mangoceuticals Inc.
- Price
- $26.01-0.80%
- $0.43+8.01%
- Market cap
- $435.2M
- $7.1M
- 1M return
- +143.08%
- +34.71%
- 1Y return
- -72.94%
- -75.84%
- Industry
- Misc Health and Biotechnology Services
- Misc Health and Biotechnology Services
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- 2023
- News (4w)
- 7
- 0
- Recent ratings
- 25
- 0
AGL
agilon health inc.
agilon health, inc. offers healthcare services for seniors through primary care physicians in the communities of the United States. The company was formerly known as Agilon Health Topco, Inc. and changed its name to agilon health, inc. in March 2021. The company was founded in 2016 and is based in Long Beach, California.
Latest AGL
- SEC Form DEFA14A filed by agilon health inc.
- SEC Form DEF 14A filed by agilon health inc.
- SEC Form 4 filed by Zamore Denise
- SEC Form 4 filed by Venkatachaliah Girish
- SEC Form 4 filed by Gertsch Timothy
- SEC Form 4 filed by Shaker Benjamin
- agilon health Sets Date to Report First Quarter 2026 Financial Results
- SEC Form 4 filed by Schwaneke Jeffrey A.
- SEC Form 4 filed by Shaker Benjamin
- SEC Form 4 filed by Gertsch Timothy
Latest MGRX
- SEC Form 10-K filed by Mangoceuticals Inc.
- SEC Form NT 10-K filed by Mangoceuticals Inc.
- SEC Form 4 filed by Cohen Jacob D.
- SEC Form 4 filed by Cohen Jacob D.
- Mangoceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Mangoceuticals Announces Lawsuit Seeking Damages Exceeding $73 Million Against Former Technology Consulting and Software Development Firm, Clarity Ventures, Inc.
- Mangoceuticals, Inc. Announces PCT Patent Filing for MGX-0024 Antiviral Technology to Include Inhibiting Respiratory or Orally Acquired Virus Infection in Animals or Birds
- Mangoceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Mangoceuticals' Patented MGX-0024 Achieves Zero Respiratory-Related Mortality in 29,000-Bird Field Trials and Demonstrates Prophylactic Benefit Against H5N1 in Controlled Government Study
- Mangoceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits